LLNW has gone up the day prior to earnings every quarter and drops like a rock the day of earnings.
Sold BZUN just now @44.44..I'll but back once it starts ticking up.. Virtually no competition huge upside.
Crazy as it seems I bought ADVL for 7.71...for the "scenario" play.
They have the goods IMO and JAZZ has no choice..if JAZZ isn't the buyer some will be..No doubt in my mind this company pairing down for a suitor who only wants FT218
The gambler in me rears it head ...I'll only hold this till mid august or even late July ..After reading ADVL the transcript this AM it feels like a short term sell plan despite outward projections you see in every transcript ....
Super high risk!..you could easily lose 70% or quickly make somewhere around 100% with a buyout.
Don't do it.
AVDL, JAZZ08:57 07/21/20 | [h=1]SVB Leerink bullish on Avadel Pharmaceuticals, initiates with an Outperform[/h]As previously reported, SVB Leerink analyst Ami Fadia initiated coverage of Avadel Pharmaceuticals (AVDL) with an Outperform rating and $17 price target. The analyst believes management's filing strategy for FT218 can circumvent a 30-month stay and lead to approval timelines independent of any potential efforts from Jazz Pharmaceuticals (JAZZ) to delay FT218's entry. As such, Fadia thinks FT218 can launch in early 2022, before the entry of Xyrem generics in 2023. The analyst also believes the value proposition of FT218 as a once-nightly version of Jazz's Xyrem is as straightforward as it is attractive for most narcolepsy patients and can capture 25% share of the sodium oxybate market long-term, driving annual revenues of $330M. At a market cap of $475M, she believes the stock reflects a significant discount to the FT218 opportunity, and with potential approval of FT218 in late 2021, she sees it potentially driving meaningful upside to current levels. Fadia also notes that with the recent simplification of the portfolio Avadel could be an attractive acquisition target to companies with an established commercial presence in the sleep or neurology space. AVDL JAZZ |
|
---|---|---|
AVDLAvadel Pharmaceuticals$8.14 / -0.26 (-3.10%) 06:43 Today SVB LeerinkAvadel Pharmaceuticals initiated with an Outperform at SVB Leerink07/01/20 Piper SandlerAvadel sale of legacy assets 'not a surprise,' says Piper Sandler06/30/20 H.C. WainwrightAvadel Pharmaceuticals initiated with a Buy at H.C. Wainwright05/04/20 Piper SandlerAvadel Pharmaceuticals price target raised to $18 from $14 at Piper Sandler |